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Background: Epithelial-to-mesenchymal transition (EMT) has a central role in cancer progression and metastatic dissemination
and may be induced by local inflammation. We asked whether the inflammation-induced acquisition of mesenchymal phenotype
by neoplastic epithelial cells is associated with the onset of mesenchymal stromal cell-like immune-regulatory properties that may
enhance tumour immune escape.
Methods: Cell lines of lung adenocarcinoma (A549), breast cancer (MCF7) and hepatocellular carcinoma (HepG2) were
co-cultured with T, B and NK cells before and after EMT induction by either the supernatant of mixed-lymphocyte reactions
or inflammatory cytokines.
Results: EMT occurrence following inflammatory priming elicited multiple immune-regulatory effects in cancer cells resulting in
NK and T-cell apoptosis, inhibition of lymphocyte proliferation and stimulation of regulatory T and B cells. Indoleamine 2,3-
dioxygenase, but not Fas ligand pathway, was involved at least in part in these effects, as shown by the use of specific inhibitors.
Conclusions: EMT induced by inflammatory stimuli confers to cancer cells some mesenchymal stromal cell-like immune-
modulatory properties, which could be a cue for cancer progression and metastatic dissemination by favouring immune escape.
Epithelial-to-mesenchymal transition (EMT) is a well-described
pathogenetic event in cancer progression and metastasis, as cancer
cells undergoing EMT acquire highly invasive features supporting
cancer spreading. Different inducers of EMT have been identified,
including transforming growth factor-beta (TGF-b), tumour
necrosis factor-alpha (TNF-a) and Notch, Hedgehog and Wnt
molecular pathways. All these stimuli induce EMT by upregulating
trascription factors, such as Snail, Twist and Zeb1, which promote
cell polarity loss by destroying tight junctions and degrading
adhesion molecules, such as E-cadherin (Mantovani et al, 2008;
Klymkowsky and Savagner, 2009; Thiery et al, 2009; Voulgari and
Pintzas, 2009; Vetter et al, 2010; Kotsafti et al, 2012; Liu et al, 2013).
EMT process is tightly connected to inflammation. In fact,
inflammatory responses have critical roles in all the stages of
tumour development, such as cancer initiation, promotion,
malignant phenotype acquisition, intravascular dissemination and
metastasis (Mantovani et al, 2008). In addition, inflammation has
been recently identified as a key inducer of EMT during cancer
progression; for this reason, EMT is now accounted for linking
inflammation and cancer through microenvironmental modifica-
tions capable of driving tumour progression (Mantovani et al,
2008; Lo´pez-Novoa and Nieto, 2009; Grivennikov et al, 2010).
The link between EMT and cancer immune escape is still only
partially uncovered, including the mechanisms through which
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cancer cells may overcome specific immune responses or even take
advantage from the immune reaction for their own survival and
growth. However, there is a number of evidence in favour of this
link. For instance, the upregulation of some EMT-inducing factors,
such as Snail1, may induce the expression of pro-inflammatory
interleukins (IL-1, IL-6 and IL-8) (Ge et al, 1999), but at the same
time it may trigger some immunosuppressive mechanisms based
on inhibitory cytokines, regulatory T cells, impaired dendritic cell
functions and resistance to cytotoxic T cells, thus accelerating the
onset of cancer metastasis (Kudo-Saito et al, 2009; Grivennikov
et al, 2010). In addition, some cancer cell lines may downregulate
in a TGF-b-dependent manner a number of effector molecules in
CD8þ T cells, such as granzyme B, perforin and Fas ligand (FasL),
thus suppressing the generation of cytotoxic effector cells and
favouring the expansion of regulatory CD4þ T cells (Joffroy et al,
2010). Finally, cancer cells may upregulate indoleamine 2,3-
dioxygenase (IDO) enzyme and therefore drive effector lympho-
cytes (mainly T cells) towards either cell cycle arrest or apoptosis
(Uyttenhove et al, 2003; Muller et al, 2005; Lob et al, 2009a).
To better clarify the relationship between EMT and immune
escape, we investigated how neoplastic cells interact with the
immune effector cells (T, B and NK cells) before and after EMT
induction in epithelial cancer cell lines through inflammatory
priming. Our work hypothesis was that the inflammation-induced
acquisition of mesenchymal phenotype by neoplastic epithelial
cells could be associated with the onset of immune-regulatory
properties commonly displayed by mesenchymal stromal cells
(MSCs) following inflammatory priming, including IDO activation
(Krampera, 2011), thus enhancing the possibility of tumour
immune escape. In other words, MSCs and cancer epithelial cells
undergoing EMT in a inflammatory microenvironment could
share a common pattern of regulatory mechanisms favouring their
survival.
MATERIALS AND METHODS
Cell culture and EMT induction. A549 cells (lung adenocarci-
noma), MCF-7 cells (breast cancer) and HepG2 (hepatocarcinoma)
cells were grown at 37 1C in 5% CO2 atmosphere in DMEM
(Sigma-Aldrich, Steinheim, Germany) supplemented with 1%
Penicillin/streptomicyn (Invitrogen, Pasley, UK) and 10% fetal
calf serum (Invitrogen); this culture condition represented the
control (CTRL).
EMT was induced by the supernatant derived from a one-way,
1 : 1 E/T ratio mixed lymphocyte reaction (MLR) in fresh culture
medium or by adding the combination of TGF-b (10 ngml 1),
interferon-gamma (IFN-g) (10 ngml 1) and TNF-a (10 ngml 1)
to the culture medium (MIX). In both cases, cell stimulation
lasted 48 h.
RNA isolation and quantitative PCR. RNA was extracted with
TRIzol (Invitrogen) and used for quantitative PCR (qPCR)
according to the established procedures. The primers used were:
E-cadherin, forward: 50-GACACCAACGATAATCCTCCGA-30,
reverse: 50-GGCACCTGACCCTTGTACGT-30;
Vimentin, forward: 50-TCCAAGTTTGCTGACCTCTCTG-30,
reverse: 50-CAGTGGACTCCTGCTTTGCC-30;
Snail1, forward: 50-CCCAGTGCCTCGACCACTAT-30, reverse:
50-GCTGGAAGGTAAACTCTGGATTAGA-30;
Snail2, forward: 50-TGCATATTCGGACCCACACA-30, reverse:
50-TGTTGCAGTGAGGGCAAGAA-30;
Zeb1, forward: 50-GATCCAGCCAAATGGAAATCA-30, reverse:
50-GGCGGTGTAGAATCAGAGTCATTC-30;
Ido1, forward: 50-GCTAAAGGCGCTGTTGGAAA-30, reverse:
50-GGGTTCACATGATCGTGGATT-30; and
b-actin, forward: 50-CGCGAGAAGATGACCCAGAT-30, reverse:
50-GTCACCGGAGTCCATCACG-30.
Cancer cell characterisation. The following antibodies were used
to characterise cancer cell immunophenotype before and after
EMT induction: anti-CD324-PE (Biolegend, San Diego, CA,
USA), anti-vimentin (R&D System, Minneapolis, MN, USA),
anti-HLA-A,B,C-PE (BD Bioscience, San Jose, CA, USA), anti-
CD54-PE (BD Bioscience), anti-HLA-DR-PE (BD Bioscience),
and corresponding isotype controls. Cells were stained according
to the manufacturer’s instructions and analysed by FACSCanto
II (BD Bioscience). For immunofluorescence, cancer cells were
immunostained with the following antibodies: E-cadherin
(Abcam, Cambridge, MA, USA), Vimentin (Dako, Glostrup,
Denmark), relative secondary antibody (Jackson Immuno-
research, West Grove, PA, USA), and Topro3 (Invitrogen) for
nucleus counterstaining. Images were acquired with the Zeiss
LSM 510 (Zeiss, Oberkochen, Germany) confocal microscope.
Immune-regulatory properties of cancer cells. Human periph-
eral blood mononuclear cells were obtained from healthy blood
donors after written informed consent, as approved by the Ethics
Committee of Azienda Ospedaliera Universitaria Integrata Verona
(N. Prog. 1828, 12 May 2010 – ‘Institution of cell and tissue
collection for biomedical research in Onco-Hematology’). CD3þ T
cells, CD19þ B cells and CD56þ NK cells were purified from
peripheral blood using appropriate negative selection kits (Miltenyi
Biotec, Bergisch Gladbach, Germany) with at least 95% cell purity,
as evaluated by flow cytometry. Proliferation of stimulated B, T
and NK cells in co-culture with cancer cells was evaluated at day
þ 4 (B cells) and þ 7 (T and NK cells) by means of CFDA-SE
dilution method (Invitrogen), as previously described. Ratio
between effector cells and cancer cells were 1 : 1 (NK or B:cancer
cells) and 10 : 1 (T:cancer cells), according to previous setting
experiments (Di Trapani et al, 2013).
All effectors were labeled with CFDA-SE (5mM) and then co-
cultured with irradiated cancer cell lines (7000 cGy). At the end of
co-culture, only viable lymphocytes identified as CD45þ and
Topro3 cells were analysed.
The mechanisms leading to proliferation arrest and apoptosis
induction of immune effector cells were assessed by adding
a specific IDO inhibitor (L-1-methyl-tryptophan (L-1MT),
Sigma-Aldrich) (1mM) to the co-cultures after T-cell stimulation
and by evaluating FasL expression by flow cytometry and enzyme-
linked immunosorbent assay (ELISA).
Pro-apoptotic properties of cancer cells. The viability of T, B and
NK cells co-cultured with irradiated cancer cell lines (7000 rad)
was assessed by flow cytometry using the Annexin V/PI Kit
(Miltenyi Biotec). Effector cells were recognised on the basis of
their positivity for anti-human-CD45 and characterised as viable
cells (annexin V /PI ); dying cells (annexin Vþ /PI ) and dead
cells (annexin Vþ /PIþ ).
T regulatory cell subsets. The presence of T regulatory cells
subset was evaluated with the following antibodies: anti-CD45
PerCP (Miltenyi Biotec), anti-CD4APCH7 (BD Bioscence), anti-
CD8PECy7 (BD Bioscience), anti-CD25FITC (Miltenyi Biotec),
anti-FoxP3PE (Miltenyi Biotec), and anti-ki67Alexa647 to track
proliferation (eBioscience, San Diego, CA, USA).
B regulatory cell subsets. The presence of B regulatory cells subset
was evaluated with the following antibodies: anti-ki67Alexa647
(eBioscience), anti-CD45PerCP (Miltenyi Biotec), anti-CD24FITC
(Miltenyi Biotec), and anti-CD38APC (Miltenyi Biotec).
Statistical analysis. Data were expressed as mean±s.d. A one-way
analysis of variance and Bonferroni’s correction for multiple
comparisons were used to determine statistical significance
(Po0.05).
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RESULTS
Induction of EMT in cancer cell lines through inflammatory
priming. Cell lines of lung adenocarcinoma (A549), breast
cancer (MCF7) and hepatocellular carcinoma (HepG2) were
induced to undergo EMT by adding to the culture medium for
48 h either MLR supernatant or a cytokine combination (MIX)
consisting of TGF-bþ IFN-gþTNF-a, as described in Materials
and methods section. Both stimuli resulted in capable of
inducing EMT features in all the three cancer cell lines
(Figure 1). The combination of the three cytokines as well as
TGF-bþTNF-a were mostly effective in inducing EMT. The
effect of each cytokine alone or in combination with the others is
described in Supplementary Figure S1. In particular, A549 cancer
cells showed a significant transcription enhancement of snail1
and snail2 genes and downmodulation of cdh1 gene (E-cadherin)
expression following both MLR and MIX treatment. Vimentin
transcript levels were significantly upregulated only with the
MIX treatment (Figure 1A, left panel). At the protein level,
flow cytometric analysis showed the significant reduction of
E-cadherin expression and upregulation of ICAM-1 and HLA
A, B, C proteins following MLR and MIX treatment. Again,
vimentin protein was upregulated only with MIX treatment. No
significant difference in HLA-DR protein expression was found
(Figure 1A, middle panel). EMT-like morphological changes
(from cubblestone to isolated cells), E-cadherin protein loss and
vimentin upregulation were confirmed by in situ immunofluor-
escence (Figure 1A, right panel).
Similarly, MCF7 cancer cells treated with either MLR super-
natant or cytokine MIX combination showed a significant increase
of snail1 and snail2 transcripts, as compared with normal culture
conditions. Vimentin and zeb1 gene expression was significantly
upregulated only with MIX treatment while cdh1 gene expression
was not changed (Figure 1B, left panel). At the protein level, both
MLR and MIX treatment induced the significant reduction of
E-cadherin expression, whereas ICAM-1, HLA-A, B, C and HLA-
DR were upregulated (Figure 1B, middle panel). Again, EMT-like
morphological changes, E-cadherin protein loss and vimentin
upregulation were confirmed by in situ immunofluorescence
(Figure 1B, right panel).
Finally, HepG2 cancer cells after MLR and MIX treatment
showed a significant transcription enhancement of snail1, zeb1 and
vimentin genes. Snail2 was upregulated only with MIX treatment,
while CDH1 gene expression resulted downregulated only with
MLR treatment, having MIX the opposite effect (Figure 1C, left
panel). Flow cytometry showed a significant E-cadherin down-
modulation and ICAM-1 expression increase after both MLR and
MIX treatment. Vimentin protein upregulation was significantly
higher with MIX treatment. The expression of HLA-A, B, C and
HLA-DR was not changed by the treatments (Figure 1C, left
panel). In situ immunofluorescence confirmed the EMT-like
morphological changes, E-cadherin protein loss and the slight
vimentin upregulation observed by flow cytometry (Figure 1B,
right panel).
Cancer cell effects on NK cells following EMT. A549, MCF7 and
HepG2 cells, either at basal conditions or after EMT induction with
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Figure 1. Evaluation of EMT changes in three cancer cell lines. Left panel: Evaluation of EMT changes by qRT–PCR on (A) A549, (B) MCF7 and (C)
HepG2 cancer cell lines in control medium (CTRL, white columns) and after the treatment for 48 h with either MLR (light grey columns) or cytokine
MIX combination (dark grey columns). The panel shows the expression of the mesenchymal genes snai1, snai2, zeb1 and vimentin (vim), and the
epithelial gene E-cadherin (cdh1). Data are shown as mean (±s.d.) and from three independent experiments; *Po0.01; **Po0.03; ***Po0.05.
Middle panel: Evaluation of EMT changes by flow cytometry on A549 (A), MCF7 (B) and HepG2 (C) cancer cell lines in the same conditions as
described above (CTRL, white columns; MLR, light grey columns; MIX, dark grey columns). Data are expressed as marker/isotype fluorescence
ratio (n¼3) (±s.d.). Dotted line represents the isotype negative control. Statistical significance compared with control condition: *Po0.01;
**Po0.03; ***Po0.05. Right panel: Evaluation of EMT changes by immunofluorescence (representative case) on A549 (A), MCF7 (B) and HepG2
(C) cancer cell lines in the same conditions as described above (CTRL, MLR, MIX). E-cadherin (green), vimentin (red), nuclei (blue).
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MLR- or MIX-priming, were co-cultured with stimulated NK cells
(Figures 2A–C). At the end of co-culture (day þ 6), NK cells were
analysed by flow cytometry to assess viability (left panels) and
proliferation rate (right panels). NK cell-mediated lysis of cancer
cells was also assessed, without showing significant changes
between basal and EMT conditions (Supplementary Figure S2).
NK cell viability after co-culture with A549 cells at basal
conditions (CTRL) was higher (78.3±5.5%) than using NK cells
alone (60.3±10%) (Figure 2A, left panel). However, in co-culture
conditions with MLR- or MIX-primed A549, NK cell viability
decreased significantly and reached comparable levels to the
condition with NK cells only (MLR-primed: 65±1.2%; MIX-
primed 66±2.0%; Figure 2A, left panel). Viable NK cell
proliferation was also assessed by flow cytometry (Figure 2A, right
panel). The co-culture with A549 cells at basal conditions increased
NK cell proliferation (163±17%, as compared with basal
proliferation values normalised to 100%). However, when co-
cultured with MLR- or MIX-primed A549, NK cells proliferated
significantly less than in the co-culture with A549 at basal
conditions (MLR-primed: 114.2±1.5%; MIX-primed: 89±14%).
NK cells in co-culture with MCF7 did not show significant
changes in viability in any of the culture conditions (NK only:
60.3±10%; MCF7 CTRL: 68±19.6%; MLR-primed: 59.6±13.0%;
MIX-primed: 53±20.0%; Figure 2B, left panel). By contrast, the
proliferation of viable NK cells in co-culture with MCF7, both at
basal conditions (CTRL) and with MLR- or MIX-primed MCF7,
was reduced as compared with the condition with NK cells only
(MCF7 CTRL: 89±14%; MLR-primed: 52±2.8%; MIX-primed:
46±5.4%; NK cells only: 100%; Figure 2B, right panel). NK cell
proliferation was also significantly reduced by both MLR- and
MIX-priming as compared with the co-culture with MCF7 at basal
conditions (Figure 2B, right panel).
NK cell viability did not change significantly when cells were
cultured with HepG2 at resting conditions and after MLR priming
(NK cells only: 60.3±10%; HepG2 CTRL: 60±5.5%, MLR-primed:
48±7.9%) but decreased in co-culture with MIX-HepG2 cells
(MIX-primed: 42±4.5%) (Figure 2C, left panel). Viable NK cell
proliferation, as assessed by flow cytometry, was higher when NK
cells were co-cultured with MLR- or MIX-primed HepG2, as
compared with the condition with NK cells only (MLR-primed:
146.6±20.2%; MIX-primed: 146±21.6%; NK only: 100%;
Figure 2C, right panel). No significant differences were found
among the three co-culture conditions of NK cells with HepG2
cells (HepG2 CTRL: 113±14.4%; MLR-primed: 146.6±20.2%;
MIX-primed: 146±21.6%; Figure 2C, right panel).
Cancer cell effects on B cells following EMT. A549, MCF7 and
HepG2 cells, either at basal conditions or after EMT induction with
MLR- or MIX-priming, were co-cultured with stimulated B cells.
At the end of the co-culture (day þ 4), B cells were analysed
by flow cytometry to assess viability and proliferation rate.
In addition, the presence of B regulatory cells (CD56þ
CD24hiCD34hi) was also assessed (Figures 3A–C).
The viability of B cells, either cultured alone or in co-culture
with A549 before and after EMT induction with MLR- or MIX-
priming, did not change significantly (B cells only: 75.6±9.9%;
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Figure 2. Effect of cancer cells, before and after EMT, on NK cells. Activated NK cells were cultured alone or with (A) A549, (B) MCF7 and (C)
HepG2 cells, either at basal conditions (CTRL) or after EMT induction with MLR or MIX priming. The left histograms show NK cell viability; white
bar: viable cells; grey bar: annexin Vþ cells; black bar: annexin Vþ /PIþ cells. The right histograms show the proliferation rate of viable NK cells;
striped column: NK cells only; white column (CTRL): NK cells co-cultured with cancer cells at basal conditions (control); grey column: NK cells co-
cultured with MLR-primed cancer cells; black column: NK cells co-cultured with MIX-primed cancer cells. Error bars: s.d. Statistical significance
compared with basal condition (NK cell only): *Po0.01; **Po0.03; ***Po0.05. Statistical significance compared with cancer cell CTRL condition:
þPo0.01; þ þPo0.03; þ þ þPo0.05.
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A549 CTRL: 57.6±2.5%; MLR-primed: 61±6.2%; MIX-primed:
56.6±3.4%; Figure 3A, left panel). Viable B-cell proliferation was
higher in the presence of cancer cells but not significantly different
in the three co-culture conditions (B cells only: 100%; A549 CTRL:
203±12.2%; MLR-primed: 165±32.3%; MIX-primed: 166±33.9%;
Figure 3A, middle panel). In addition, no B regulatory cells were
found in any of the culture conditions (Figure 3A, right panel).
The viability of B cells was significantly affected by the co-
culture with MCF7 cells (B cells only: 87.6±2.0%; MCF7 CTRL:
28.6±5.5%; MLR-primed: 16±5.7%; MIX-primed: 7±5.3%;
Figure 3B, left panel). In addition, the treatment of MCF7 with
MLR- and MIX-priming significantly increased the percentage of
preapoptotic and dead B cells, as compared with MCF7 in control
conditions (Figure 3B, left panel). The effect of MLR- and MIX-
priming was also evident by analysing viable B-cell proliferation (B
cells only: 100%; MCF7 CTRL: 99±3.2%; MLR-primed:
86.2±3.8%; MIX-primed: 72.1±4.3%; Figure 3B, middle panel).
On the contrary, no significant differences were found by
comparing the condition with B cells only to B cells co-cultured
with MCF7 CTRL. Finally, a significant increase in B regulatory
cells was found in the co-culture condition of B cells with MCF7
only after MIX-priming (Figure 3B, right panel).
No significant differences were found in the viability of B cells
alone or in co-culture with HepG2 cancer cells in any of the culture
conditions (B cells only: 87±2.0%; HepG2 CTRL: 89.9±4.6%;
MLR-primed: 91.6±2.89%; MIX-primed: 92.4±1.56%; Figure 3C,
left panel). The analysis of viable B-cell proliferation did not show
any significant difference among the different co-culture condi-
tions (CTRL, MLR, MIX) but instead revealed that HepG2 cells,
regardless their EMT status, strongly supported B-cell proliferation
(B cells only: 100%; HepG2 CTRL: 275.3±21.6%; MLR-primed:
298.6±26.5%; MIX-primed: 304.6±36%; Figure 3C, middle
panel). No B regulatory cells were detected in any of the culture
conditions (Figure 3C, right panel).
Cancer cell effects on T cells following EMT. A549, MCF7 and
HepG2 cells in control conditions and MLR- or MIX-primed were
co-cultured with stimulated T cells (Figures 4A–C, respectively). At
the end of the co-culture (day þ 6), the immune effector cells were
analysed by flow cytometry to measure cell viability (left panel)
and proliferation (middle panel). In addition, the presence of
T regulatory cells (CD4þCD25þFoxP3þ ) was evaluated (right
panel).
The viability of T cells alone or in co-culture with A549 cells did
not change significantly among the different conditions (T cells
only: 74.4±2.4%; MCF7 CTRL: 44±15.4%; MLR-primed:
51±22.2%; MIX-primed: 58±18.2%; Figure 4A, left panel). On
the contrary, the proliferation of viable T cells was dramatically
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Figure 3. Effect of cancer cells, before and after EMT, on B cells. Activated B cells were cultured alone or with (A) A549, (B) MCF7 and (C) HepG2
cells, either at basal conditions (CTRL) or after EMT induction with MLR or MIX priming. The left histograms show B-cell viability; white bar: viable
cells; grey bar: annexin Vþ cells; black bar: annexin Vþ /PIþ cells. The middle histograms show the proliferation rate of viable B cells; striped
column: B cells only; white column (CTRL): B cells co-cultured with cancer cells at basal conditions (control); grey column: B cells co-cultured with
MLR-primed cancer cells; black column: B cells co-cultured with MIX-primed cancer cells. Dot plots (right panel): gated region of the B-cell
regulatory population (representative cases). Error bars: s.d. Statistical significance compared with basal condition (B-cell only): *Po0.01;
**Po0.03; ***Po0.05. Statistical significance compared with CTRL cancer cell condition: þPo0.01; þ þPo0.03; þ þ þPo0.05.
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affected by co-culture with A549 (T cells only: 100%; A549 CTRL:
51.5±2.9%; MLR-primed: 16.1±4.6%; MIX-primed: 10.4±7.5%;
Figure 4A, middle panel). The proliferation of viable T cells was
also significantly reduced when T cells were co-cultured with A549
after MLR- and MIX-priming (Figure 4A, middle panel). The
analysis of the different T-cell subsets in co-culture with A549 did
not reveal any significant change in the balance of T CD4þ ,
CD8þ and T regulatory cells among the different culture
conditions (Figure 4A, right panel).
In the presence of MCF7 cells, T-cell viability did not change
significantly (T cells only: 69.5±10%; T cells in co-culture with
MCF7 CTRL: 48.6±4.5%; Figure 4B, left panel). However, after
MLR- and MIX-priming, T-cell viability significantly lowered (T
cells only: 69.5±10%; MCF7 CTRL: 48.6±4.5%; MLR-primed:
24.7±3.5%; MIX-primed: 27.5±10%; Figure 4B, left panel). Viable
T-cell proliferation did not vary in different culture conditions (T
cells only: 100%; MCF7 CTRL: 79±9.9%; MLR-primed:
91±11.2%; MIX-primed: 96±12.3%; Figure 4B, middle panel).
A significant increase in the amount of T regulatory cells was
observed when T cells were co-cultured with MCF7, regardless of
their EMT status (T cells only: 1%; MCF7 CTRL: 2.57±0.25%;
MLR-primed: 7.2±1.8%; MIX-primed: 7.5±1.8%; Figure 4B, right
panel). However, MLR- and MIX-priming induced a significantly
higher amount of T regulatory cells in comparison to what was
observed when T cells were co-cultured with MCF7 in control
conditions (Figure 4B, right panel).
Finally, T-cell viability was significantly lower in all the co-
culture conditions with HepG2 cells (T cells only: 70±8.4%;
HEPG2 CTRL: 37±8.8%; MLR-primed: 26±7.6%; MIX-primed:
25±6.0%; Figure 4A, left panel). A statistically significant decrease
was also observed by comparing the viability of T cells in co-
culture with MIX-primed HepG2 vs HepG2 CTRL (Figure 4C,
middle panel). Viable T-cell proliferation was reduced regardless of
HepG2 EMT status (T cells only: 100%; HEPG2 CTRL: 82±4.3%;
MLR-primed: 79±4.6%; MIX-primed: 81±8.8%; Figure 4C,
middle panel). Similarly, a significant increase in the amount of
T regulatory cells was observed regardless of HepG2 EMT status (T
cells only: 1%; HepG2 CTRL: 3.15±0.61%; MLR-primed:
7.14±0.96%; MIX-primed: 8.57±1.85%; Figure 4C, right panel).
However, MLR- and MIX-priming induced a significantly higher
amount of T regulatory cells in comparison to what observed when
T cells were co-cultured with HepG2 in control conditions
(Figure 4C, right panel).
Mechanisms involved in cancer cell immunomodulation follow-
ing EMT. As MCF7 and HepG2 had a prevalent pro-apoptotic
effect on T cells, while A549 mainly inhibited T-cell proliferation
without inducing significant apoptosis, we investigated the
involvement of FasL and IDO pathways in the immunomodulatory
properties acquired by cancer cells after EMT induction.
FasL protein expression by flow cytometry was undetectable in
all the cancer cell lines both before and after EMT induction with
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either MLR- or MIX-priming (data not shown). In addition, ELISA
assay did not detect significant concentrations of soluble FasL in
the cell supernatants of any of the culture conditions (data not
shown).
The involvement of IDO in the immunomodulatory properties
of cancer cells was first measured by qRT–PCR (Figure 5A). After
MLR- and MIX-priming, all the cell lines significantly upregulated
ido1 transcription, particularly following MIX-priming (normal-
ised expression of ido1 in A549 CTRL: 1; in MLR-primed A549:
4313; in MIX-primed A549: 46 666; in MCF7 CTRL: 1; in MLR-
primed MCF7: 478; in MIX-primed MCF7: 22 626; in HepG2
CTRL: 1; in MLR-primed HepG2: 400; in MIX-primed HepG2:
4000; Figure 5A). In addition, after EMT induction with MLR- or
MIX-priming, ido1 resulted in overexpression at the protein level
in all the three cancer cell lines (Figure 5B). In particular, ido1 level
was higher and paralled EMT evidence following MIX-priming, as
confirmed by E-cadherin downmodulation and increased expres-
sion of Snail1 (Figure 5B). IFN-g was the main inflammatory
cytokine responsible for this effect, further enhanced by TNF-a.
In fact, EMT induction in the absence of IFN-g, that is, with
either TGF-b only or TGF-bþTNF-a, did not determine a
significant IDO-1 upregulation (Supplementary Figure S1), thus
paralleling MSC behavior following inflammatory priming
(Krampera, 2011).
To test IDO effect, T-cell viability and proliferation assays were
repeated with or without the specific inhibitor of IDO, that is,
L-1MT. The inhibition of T-cell proliferation with A549 cells in
control conditions and after MLR- and MIX-priming was almost
completely restored in the presence of L-1MT (A549 CTRL:
51.5±2.9%; A549 CTRLþ L-1MT: 88±5.5%; MLR-primed A549:
16.1±4.6%; MLR-primed A549þ L-1MT: 82.6±5.8%; MIX-
primed A549: 10.4±7.5%; MIX-primed A549þ L-1MT:
82.3±7.3%; Figure 5C, left panel). Similar results on T-cell
proliferation were obtained by adding L-1MT to the co-culture of
T cells with MCF7 and HepG2 cell lines following EMT induction
(MLR-primed MCF7: 24.7±3.5%; MLR-primed MCF7þ L-1MT:
59±9.43%; MIX-primed MCF7: 27.5±10%; MIX-primed
MCF7þ L-1MT: 62±9.1%; MLR-primed HepG2: 26±7.6%;
MLR-primed HepG2þ L-1MT: 73.6±5.2%; MIX-primed HepG2:
25±6.0%; MIX-primed HepG2þ L-1MT: 78±7.9%), but not with
MCF7 and HepG2 at basal conditions (MCF7 CTRL: 48.6±4.5%;
MCF7 CTRLþ L-1MT: 52±6.9%; HepG2 CTRL: 37±8.8%;
HepG2 CTRLþ L-1MT: 45.6±6.8%; Figure 5C, middle and right
panels). As expected, the addition of L-1MT to the culture media
did not change significantly the amount of T regulatory cells
induced by the co-culture of T cells with MCF7 and HepG2 (data
not shown).
DISCUSSION
EMT molecular mechanisms have been extensively studied as they
are a key step towards tumour development and dissemination
through the induction of highly invasive cancer phenotype. In
addition, EMT may drive the inflammatory reactions occurring
during cancer development and, in turn, is influenced by
the inflammatory microenvironment (Mantovani et al, 2008;
Lo´pez-Novoa and Nieto, 2009; Grivennikov et al, 2010). However,
how cancer cells may affect the immune system during EMT is still
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only partially uncovered (Uyttenhove et al, 2003; Kudo-Saito et al,
2009; Lob et al, 2009a; Joffroy et al, 2010).
In this study, we hypothesised that cancer epithelial cells
undergoing EMT following inflammatory priming may acquire at
least some of the typical inhibitory properties commonly expressed
by MSCs, including IDO activation (Krampera, 2011), which
would give some cues to explain their capability of surviving in a
potentially hostile inflammatory microenvironment and escaping
the specific anti-tumour immune response.
According to our hypothesis, we demonstrate here that EMT can
be triggered by cytokines normally produced by the inflammatory
microenvironment (TGF-b, TNF-a and IFN-g), as well as by the
supernatant derived from in vitro immune reactions, such as MLR.
Inflammatory-induced EMT promotes a number of variable
immune-modulatory mechanisms depending on the cancer cell
origin, including: interference with proliferation of NK and B cells
(A549 and MCF-7 cell lines) and T cells (A549 and HepG2);
apoptosis induction on NK cells (A549 and HepG2 cell lines), B cells
(MCF7 cell line) and T cells (MCF7 and HepG2 cell lines); and
expansion of both regulatory T (MCF7 and HepG2 cell lines) and B
cells (MCF7 cell line). All the above-mentioned mechanisms of
immune modulation are shared by MSCs of different origin, except
apoptosis induction on immune effector cells, which is rarely
observed with MSCs (Krampera, 2011; Di Trapani et al, 2013) and
therefore seems to be a peculiar feature of cancer cells undergoing
EMT (Uyttenhove et al, 2003; Muller et al, 2005; Lob et al, 2009a). In
any case, we confirm that IDO pathway after EMT induction by
inflammatory stimuli is an important, although not unique,
molecular mechanism responsible for T-cell inhibition, as previously
shown (Uyttenhove et al, 2003; Muller et al, 2005; Lob et al, 2009a);
by contrast, Fas–FasL pathway does not seem to be involved in T-cell
apoptosis induction, at least under these experimental conditions.
As previously mentioned, a different pattern of inhibitory
mechanisms following inflammation-induced EMT has been found
depending on the origin of cancer cell lines. In particular, A549
cells deriving from lung adenocarcinoma appear to influence
immune reactions mainly by reducing NK cell viability and
proliferation, and hampering T-cell proliferation, without signifi-
cant induction of regulatory B and T cells. By contrast, MCF-7
cells, deriving from breast cancer, is capable of affecting NK cell
proliferation without inducing apoptosis, significantly impair
B-cell functions by lowering their viability and proliferation and
inducing B regulatory cells and hamper T-cell response through
both pro-apoptotic effects, without modifying proliferation rate,
and induction of T regulatory cells. Finally, HepG2 cells, deriving
from hepatocarcinoma, clearly hamper T-cell functions by both
inhibiting survival and inducing T regulatory cells; however, they
have opposite effects on NK cells, by inducing both cell apoptosis
and proliferation, and B cells, whose proliferation is supported,
thus probably selecting some NK and B-cell subsets that might be
instrumental to HepG2 cell survival (Table 1).
Some of the peculiarities can be explained by the immunophe-
notypic differences of the three cell lines in the expression,
following EMT induction, of class I (upregulated by A549 and
MCF7) and II (upregulated by A549 and MCF7) HLA molecules,
in the absence of co-stimulatory molecule expression, such as CD80
and CD86 (data not shown), thus leading to the lack of NK cell
activation or T- and B-cell anergy (Schwartz, 1990; Diederichsen
et al, 2003; Chang et al, 2005). However, other functional properties,
such as the induction of B regulatory cells by MCF7 cell line and T
regulatory cells by MCF7 and HepG2 cell lines, are probably related
to the tissue of origin and the specific molecular pathways triggered
by inflammatory-mediated EMT induction. Nevertheless, both B
and T regulatory cells have been recently associated with tumour
progression and are reciprocally linked (Olkhanud et al, 2011;
Balkwill et al, 2013); in addition, T regulatory cells may impair
survival and proliferation of activated CD4þ and CD8þ T cells
(Grossman et al, 2004; Viguer et al, 2004).
Our data further confirm the important role of IDO pathway in
T-cell inhibition by cancer cells following inflammation-induced
EMT, regardless of their tissue of origin. IDO creates an
immunosuppressive microenvironment by depleting tryptophane
and accumulating kynurenine metabolites (Fallarino et al, 2006;
Platten et al, 2012), and it is a general mechanism of immune
modulation shared by MSCs both in normal and cancer
microenvironment (Krampera, 2011; Ling et al, 2014). IDO
expression has been used in cancer patients as a biomarker to
monitor disease activity and response to therapy (Riesenberg et al,
2007; Platten et al, 2012), as its expression is increased in many
cancer cell types (Ge et al, 2000a; Tajiri et al, 2003); consequently,
specific IDO inhibitors have been suggested for cancer therapy
(Lob et al, 2009b).
In summary, our work shows that the acquisition through
inflammatory stimuli of mesenchymal phenotype by cancer cells of
different origin is associated with the onset of MSC-like immune-
regulatory functions and some additional properties, such as
apoptosis induction in immune effector cells, which all may lead to
tumour immune escape and, consequently, to cancer progression
and metastatic dissemination.
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